← Eichor
Condition: Injection Site Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Injection Site

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection
Phase 2 · 39 location(s) · TG Therapeutics, Inc. · NCT07503873A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging
NA · 1 location(s) · RenJi Hospital · NCT06763354Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07193654Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Phase 1/Phase 2 · 3 location(s) · SpectraCure AB · NCT06807359A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/Phase 2 · 43 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06431490A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Canc
Phase 3 · 31 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07008976A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
Phase 1 · 4 location(s) · Kortuc, Inc. · NCT05570422Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
Phase 1/Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06759064Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1 · 1 location(s) · Shanghai Chest Hospital · NCT06663306Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Coordination Pharmaceuticals, Inc. · NCT05838729Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NA · 9 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07095023Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04952272X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Phase 1 · 4 location(s) · Immunolight, LLC · NCT04389281A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Soli
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07232524Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Phase 1 · 1 location(s) · Ryan Carey · NCT06747390The Optimal Injection Site for a 3D Guided Inferior Alveolar Nerve Block Device (IANBD)
NA · 1 location(s) · Boston University · NCT06676098A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07241767A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumo
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05785039A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prost
Phase 1/Phase 2 · 2 location(s) · Yunhe Pharmaceutical (Tianjin) Co., Ltd · NCT06970119A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06114511A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07071714A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatmen
Phase 2 · 1 location(s) · Shanghai Cancer Hospital, China · NCT06901817A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06718205Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
Phase 4 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07092202Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07290270
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.